Zydus Lifesciences Limited has informed the Exchange regarding a press release dated April 30, 2025, titled "Zydus receives final approval from USFDA for Niacin Extended-Release Tablets USP, 500 mg, 750 mg, and 1,000 mg".
Press Release Apr 30 2025
Filed with NSE ·
6ix hasn’t read this filing yet.
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Apr 26 2025
- Press Release Apr 25 2025
- ITC Reversal Of Common ITC U/s17(2) Required In Relation To Activity Of Subscription And Redemption Of Mutual Funds
- Press Release Apr 17 2025
- Press Release Apr 16 2025
Later from Zydus Lifesciences
- Zydus Receives Final Approval From USFDA for Glatiramer Acetate Injection, the Generic Version of Copaxone® 20 mg/ml, 40 mg/ml, Single-Dose Prefilled Syringes
- Press Release May 08 2025
- Press Release May 14 2025
- Press Release May 20 2025
- Press Release May 23 2025
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences